用于药物输送应用的新型壳聚糖/卡拉胶纳米粒子的开发。
Development of new chitosan/carrageenan nanoparticles for drug delivery applications.
机构信息
Department of Polymer Engineering, University of Minho, Portugal.
出版信息
J Biomed Mater Res A. 2010 Mar 15;92(4):1265-72. doi: 10.1002/jbm.a.32466.
The use of polymeric nanoparticles, especially those composed of natural polymers, has become a very interesting approach in drug delivery, mainly because of the advantages offered by their small dimensions. The aim of this work was to develop a novel formulation of nanoparticles comprised of two natural marine-derived polymers, namely chitosan and carrageenan, and to evaluate their potential for the association and controlled release of macromolecules. Nanoparticles were obtained in a hydrophilic environment, under very mild conditions, avoiding the use of organic solvents or other aggressive technologies for their preparation. The developed nanocarriers presented sizes within 350-650 nm and positive zeta potentials of 50-60 mV. Polymeric interactions between nanoparticles' components were evaluated by Fourier transform infrared spectroscopy. Using ovalbumin as model protein, nanoparticles evidenced loading capacity varying from 4% to 17% and demonstrated excellent capacity to provide a controlled release for up to 3 weeks. Furthermore, nanoparticles have demonstrated to exhibit a noncytotoxic behavior in biological in vitro tests performed using L929 fibroblasts, which is critical regarding the biocompatibility of those carriers. In summary, the developed chitosan-carrageenan nanoparticles have shown promising properties to be used as carriers of therapeutic macromolecules, with potential application not only strictly in drug delivery, but also in broader areas, such as tissue engineering and regenerative medicine.
聚合物纳米粒子的应用,特别是那些由天然聚合物组成的纳米粒子,已成为药物传递的一种非常有趣的方法,主要是因为它们的小尺寸带来了优势。本工作旨在开发一种由两种天然海洋衍生聚合物壳聚糖和卡拉胶组成的新型纳米粒子制剂,并评估其用于大分子的结合和控制释放的潜力。纳米粒子是在亲水环境中,在非常温和的条件下制备的,避免了有机溶剂或其他用于制备纳米粒子的苛刻技术的使用。所开发的纳米载体的粒径在 350-650nm 之间,zeta 电位为 50-60mV。通过傅里叶变换红外光谱评估纳米粒子成分之间的聚合物相互作用。使用卵清蛋白作为模型蛋白,纳米粒子的载药量在 4%-17%之间变化,并表现出极好的控制释放能力,可达 3 周。此外,在使用 L929 成纤维细胞进行的体外生物学试验中,纳米粒子表现出非细胞毒性行为,这对于那些载体的生物相容性至关重要。总之,所开发的壳聚糖-卡拉胶纳米粒子具有作为治疗性大分子载体的应用潜力,不仅在药物传递方面,而且在组织工程和再生医学等更广泛的领域也具有应用前景。